New hope for rare cancers? eribulin tested in angiosarcoma and EHE
NCT ID NCT03331250
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tested the drug eribulin in 13 people with two rare cancers that start in blood vessels: angiosarcoma and epithelioid hemangioendothelioma (EHE). Participants had advanced disease that had already been treated. The main goal was to see if eribulin could shrink tumors. Researchers also tracked how long the cancer stayed under control and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.